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Tenomodulin promotes human adipocyte
differentiation and beneﬁcial visceral adipose
tissue expansion
Ozlem Senol-Cosar1, Rachel J. Roth Flach1, Marina DiStefano1, Anil Chawla1, Sarah Nicoloro1, Juerg Straubhaar1,
Olga T. Hardy2, Hye Lim Noh1,3, Jason K. Kim1,3, Martin Wabitsch4, Philipp E. Scherer2 & Michael P. Czech1
Proper regulation of energy storage in adipose tissue is crucial for maintaining insulin sen-
sitivity and molecules contributing to this process have not been fully revealed. Here we show
that type II transmembrane protein tenomodulin (TNMD) is upregulated in adipose tissue of
insulin-resistant versus insulin-sensitive individuals, who were matched for body mass index
(BMI). TNMD expression increases in human preadipocytes during differentiation, whereas
silencing TNMD blocks adipogenesis. Upon high-fat diet feeding, transgenic mice over-
expressing Tnmd develop increased epididymal white adipose tissue (eWAT) mass, and
preadipocytes derived from Tnmd transgenic mice display greater proliferation, consistent
with elevated adipogenesis. In Tnmd transgenic mice, lipogenic genes are upregulated in
eWAT, as is Ucp1 in brown fat, while liver triglyceride accumulation is attenuated. Despite
expanded eWAT, transgenic animals display improved systemic insulin sensitivity, decreased
collagen deposition and inﬂammation in eWAT, and increased insulin stimulation of Akt
phosphorylation. Our data suggest that TNMD acts as a protective factor in visceral adipose
tissue to alleviate insulin resistance in obesity.
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A
large body of work has suggested that adipose tissue plays
a key role in determining metabolic health as a major
regulator of carbohydrate and lipid homeostasis. Expan-
sion of adipose tissue in overweight or obese humans can lead to
a spectrum of dysfunctions collectively referred to as metabolic
syndrome. However, a signiﬁcant number of metabolically
healthy obese human subjects demonstrate a situation of benign
adipose tissue expansion whose differences from pathological
obesity are poorly understood1–5. Some studies have suggested
that speciﬁc physiological mechanisms and anatomical locations
of adipose expansion may differentially affect metabolic
homeostasis6–9. Major white adipose depots located in
subcutaneous regions and the visceral cavity can dynamically
expand during obesity10. In humans, adipose tissue expands via
adipocyte hypertrophy during early obesity, whereas an increase
in adipocyte number, denoted hyperplasia, also occurs in
prolonged obesity11,12. Animal models have demonstrated that
subcutaneous adipose tissue enlargement is mostly due to
hypertrophy, while the visceral depot expands by increasing
both cell size and number upon long-term high-fat diet (HFD)
feeding13,14. This increase in cell number derives from the
differentiation of adipocyte precursors into differentiated
adipocytes, a well-deﬁned process that has been extensively
modelled in the 3T3-L1 mouse cell line15,16. Though mouse
adipocyte lines such as 3T3-L1 cells have greatly contributed to
identifying the molecular mechanisms involved in differentiation
and maintaining mature adipocyte function17, interspecies
differences in gene expression and regulation between mouse
and human adipocytes are important to consider and further
investigate18,19.
Central obesity is linked to several metabolic morbidities such
as type 2 diabetes and cardiovascular disease20. Visceral adipose
tissue is more prone to inﬂammation than subcutaneous fat in
obesity through mechanisms that enhance immune cell content21
and increase pro-inﬂammatory cytokine expression22–25.
A leading hypothesis suggests that low-grade inﬂammation in
fat depots is involved in metabolic syndrome26,27. Moreover,
visceral adipose tissue may be more lipolytic than subcutaneous
adipose tissue due to dampened insulin suppression of lipolysis
and a higher response to catecholamines. This, in turn, increases
both non-esteriﬁed fatty acid release into the circulation and
hepatic lipid deposition due to the close proximity of visceral
adipose tissue to the hepatic portal vein28,29. Ectopic lipid storage
in the liver and muscle is thought to trigger insulin resistance in
these tissues, although not under all conditions30. Therefore,
promoting healthy expansion and better lipid storage in visceral
adipose tissue is crucial to maintain glucose homeostasis and
insulin sensitivity.
To identify and explore mechanisms in adipose tissues that
either cause insulin resistance or preserve insulin sensitivity in
obese individuals, we compared gene expression in subcutaneous
and omental adipose tissues from obese human subjects matched
for body mass index (BMI) but differing in insulin resistance.
Among several differentially expressed genes identiﬁed, we
focused on tenomodulin (TNMD), a type II transmembrane
protein, due to its high and predominant expression in human
adipose tissue, also noted by others31,32. Comparative analysis of
adipose tissue TNMD expression in obese and lean individuals
also previously indicated that TNMD is strongly correlated with
BMI31,33,34. Moreover, many genome-wide association studies
revealed that single-nucleotide polymorphisms in the TNMD
gene are associated with various metabolic characteristics such as
BMI, serum low-density lipoprotein levels and inﬂammatory
factors35–37. Though these studies indicate a potential role for
TNMD in human adipose tissue, the function of TNMD has not
been evaluated.
Here by gene silencing and generating a transgenic mouse line,
we demonstrate that TNMD is required for adipocyte differentia-
tion, and overexpression of Tnmd in adipose tissue protects mice
from obesity-induced systemic insulin resistance. These data
suggest that adipocyte TNMD is a protective factor that enhances
insulin sensitivity in obesity, potentially via promoting hyperpla-
sia and beneﬁcial lipid storage in the visceral adipose tissue.
Results
Higher expression of human TNMD in insulin resistance. To
assess gene expression differences in insulin-resistant versus
insulin-sensitive obese individuals, total RNA was isolated from
snap-frozen adipose tissue biopsies from omental and sub-
cutaneous fat depots of human subjects undergoing bariatric
surgery, and analysed for genome-wide gene expressions. Clinical
data of the subjects used in gene expression analysis are shown in
Supplementary Table 1. DNA microarray data identiﬁed TNMD
as a gene that is signiﬁcantly upregulated in omental fat from
insulin-resistant individuals compared with BMI-matched, insu-
lin-sensitive subjects (Fig. 1a). However, no signiﬁcant difference
in TNMD gene expression was observed between the two groups
in subcutaneous adipose tissue (Supplementary Fig. 1a). These
results were validated by assessing messenger RNA (mRNA) and
protein levels using quantitative PCR with reverse transcription
(qRT–PCR) and western blotting, respectively (Fig. 1b,c). It was
previously demonstrated that white adipose tissue and primary
adipocytes have the highest expression of TNMD among human
tissues31. Although this original study claimed similar TNMD
expression in the stromal vascular fraction (SVF) and whole
adipose tissue, we observed that TNMD is predominantly
expressed in adipocytes compared with cells from the SVF in
both visceral and subcutaneous white adipose tissues (Fig. 1d;
Supplementary Fig. 1b).
To assess the role of TNMD in human adipocyte function,
we utilized human preadipocytes obtained from a subject
with Simpson–Golabi–Behmel syndrome (SGBS cells)38 and
discovered that TNMD expression increased by several hundred
fold during adipocyte differentiation in culture (Fig. 1e).
Expression of mature adipocyte markers such as PPARG2 and
ADIPOQ certiﬁed that these cells had undergone adipocyte
differentiation after induction with the adipogenic cocktail.
TNMD expression was increased even 18 h after stimulation of
the preadipocytes. Moreover, TNMD exhibited a time-dependent
expression proﬁle similar to peroxisome proliferator-activated
receptor gamma 2 (PPARG2) and CCAAT/enhancer-binding
protein alpha (C/EBPA), but not Kruppel-like factor 4 (KLF4),
which is an early transcription factor in the adipogenic cascade
(Supplementary Fig. 1c).
TNMD is required for human adipogenesis. Several studies
have demonstrated that adipose tissue expansion in obesity is
promoted by adipogenesis in addition to adipocyte hypertrophy
in both mice and humans14,39–42. Because TNMD had an
expression proﬁle that was similar to genes that are critically
involved in adipocyte differentiation and its expression is
increased in obese adipose tissue, we hypothesized that TNMD
might be involved in human adipocyte differentiation. To test this
hypothesis, TNMD was silenced in SGBS preadipocytes two days
before adipogenic stimulation (Fig. 2a). Remarkably, silencing of
TNMD signiﬁcantly attenuated differentiation as demonstrated
by substantially decreased accumulation of neutral lipids
measured by Oil Red O staining at day 14 (Fig. 2b,c). Analysis
of mature SGBS adipocytes also revealed that preadipocytes
lacking TNMD had fewer lipid droplets and lacked a
differentiated adipocyte morphology as assessed by perilipin
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(PLIN) staining (Fig. 2d). Thus, TNMD is required for human
adipocyte differentiation.
Unlike the mouse cell line 3T3-L1, human primary adipocytes
do not undergo clonal expansion43,44. SGBS cells also did not
display any increase in cell number during the ﬁrst 5 days of
differentiation (data not shown), suggesting that clonal expansion
does not occur in these cells. Therefore, full conﬂuence
is important for SGBS cells to differentiate. To assess
whether TNMD affected cell death in SGBS preadipocytes,
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide)
cell viability assay was performed to assess viability in
TNMD-silenced SGBS cells. The results show short interfering
RNA (siRNA)-mediated silencing of TNMD did not affect
viability (Supplementary Fig. 2a).
To further investigate whether TNMD is required for
adipogenic gene expression during differentiation, total mRNA
was isolated at different time points of differentiation (Fig. 2a)
and expression of adipogenic markers such as PLIN1, C/EBPA
and PPARG2 were analysed by qRT–PCR. Indeed, expression of
these genes was signiﬁcantly blunted at most of the time points
in TNMD-silenced cells compared with cells that had been
transfected with scrambled siRNA (Fig. 2e). Because the
expression of adipogenic transcription factors increases markedly
even during the ﬁrst day of differentiation, we asked whether
TNMD silencing diminishes the early induction of these
transcription factors as well as their target genes. Thus, a DNA
microarray analysis was performed in SGBS cells that had been
transfected with either scrambled or TNMD siRNA at day 1 of
differentiation. The induction of many adipogenic genes was
signiﬁcantly diminished after TNMD depletion (Supplementary
Fig. 2b). Importantly, in the absence of TNMD, stimulation of
both the early transcription factor CCAAT/enhancer-binding
protein beta (C/EBPb) as well as late transcription factors
C/EBPa and peroxisome proliferator-activated receptor gamma
(PPARg) was diminished (Fig. 2f,g; Supplementary Fig. 2c).
Although TNMD expression is low in murine adipocytes, TNMD
depletion in 3T3-L1 preadipocytes revealed that TNMD is also
required for mouse adipocyte differentiation and plays a similar
role to regulate adipogenic gene expression as in SGBS cells
(Supplementary Fig. 2d,e). These data suggest that even though
expression proﬁles are different between mature human and
mouse adipocytes, the requirement of TNMD for differentiation
is conserved between the two species.
The C-terminal domain of TNMD is similar to the secreted
and functional portion of its homologous protein chondromo-
dulin 1 (ref. 32), and studies have suggested that the C-terminal
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Figure 1 | Adipose tissue expression of TNMD in obese humans and adipocytes. Omental adipose tissue was isolated from obese patients undergoing
bariatric surgery. (a) RNA was isolated, and a microarray was performed (mean±s.e.m.; n¼6, insulin sensitive; n¼ 8, insulin resistant, *Po0.05, by
Student’s t-test). (b) Quantitative PCR validation of TNMD expression in obese individuals (mean±s.e.m.; n¼6, insulin sensitive; n¼ 8, insulin resistant,
*Po0.05, by Student’s t-test). (c) Western blot analysis of TNMD and actin in omental adipose tissue lysates from insulin-sensitive and insulin-resistant
patients (n¼4–5, P¼0.023 by Student’s t-test). (d) Quantitative PCR analysis of TNMD, PLIN1 and SPP1 expression in the stromal vascular fraction (SVF)
and in primary adipocytes isolated from omental adipose tissue of obese individuals (mean±s.e.m.; n¼9 for both SVF and primary adipocytes *Po0.05,
**Po0.01, ***Po0.001, by Student’s t-test). (e) Quantitative PCR analysis of TNMD, PPARG2 and ADIPOQ expression at various time points during
differentiation in SGBS human adipocytes (mean±s.e.m.; n¼ 3–4, *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test).
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domain of TNMD is functionally active45. We sought to
understand whether the effect of TNMD to regulate adipo-
genesis is cell autonomous. Thus, SGBS cells treated with
siTNMD were mixed with non-transfected cells in equal
numbers to determine whether wild-type TNMD rescues the
adipogenic defect in TNMD-silenced cells via a paracrine mechanism.
After adipogenic stimulation, we observed that Oil Red O staining
was diminished by B50% when control cells were co-cultured
with transfected cells, suggesting that the adipogenic effect of
TNMD is cell autonomous in vitro (Supplementary Fig. 3a).
Increased eWAT expansion in Tnmd overexpressing mice. To
gain a better understanding of the role of Tnmd in adipose tissue,
we generated transgenic mice that overexpress mouse Tnmd
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Figure 2 | siRNA-mediated silencing of TNMD attenuates differentiation in human adipocytes. SGBS preadipocytes were transfected with siRNA 2 days
before adipogenesis induction. Total RNA isolation and Oil Red O staining were performed on the stated days of differentiation. (a) Schematic
demonstration of experimental method. (b,c) Adipocytes were differentiated for 14 days in culture and stained with Oil Red O. (b) Representative images
(scale bar, 100mm). (c) Quantiﬁcation of Oil Red O staining (mean±s.e.m.; n¼4 *Po0.05, Student’s t-test). (d) Immunoﬂuorescent staining of mature
adipocytes with PLIN (green) and 4,6-diamidino-2-phenylindole (DAPI; blue; scale bar, 20mm). (e) Quantitative PCR analysis of TNMD, C/EBPA, PPARG2
and PLIN1 expression at days 0, 4, 8 and 12 of adipocyte differentiation in SGBS cells (mean±s.e.m.; n¼ 3 *Po0.05, **Po0.01, ***Po0.001).
(f) Quantitative PCR analysis of TNMD, C/EBPA, PPARG2 and PLIN1 expression at day 0 and day 1 after stimulation (mean±s.e.m.; n¼ 3 *Po0.05,
**Po0.01, ***Po0.001, by Student’s t-test). (g) Immunoblots for C/EBPb, C/EBPa, PPARg and tubulin at day 0 and day 1 of adipogenic differentiation
(n¼ 3 for C/EBPb and PPARg, n¼6 for C/EBPa, quantiﬁed in Supplementary Fig. 2 by Student’s t-test).
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under the adipose tissue-speciﬁc Adiponectin promoter (Fig. 3a).
Two transgenic lines (hereafter, line 1 and line 2) that exhibited
signiﬁcant overexpression of Tnmd in inguinal white adipose
tissue (iWAT), epididymal white adipose tissue (eWAT) and
brown adipose tissue (BAT) were utilized in these experiments
(Fig. 3b,c). qRT–PCR and western blot analysis demonstrated
that Tnmd expression was speciﬁc to adipose tissue in these mice
(Supplementary Fig. 4a,b). Given that TNMD expression is
increased during obesity in human adipose tissue31, weight gain
was assessed in the Tnmd transgenic mice. In both transgenic
lines, no weight difference was observed compared with littermate
controls after both chow and HFD-fed conditions (Fig. 3d;
Supplementary Fig. 4c). However, a signiﬁcant increase in
eWAT weight was observed in HFD-fed but not in chow-fed
transgenic animals (Fig. 3e). The transgenic mice also displayed a
concomitant decrease in liver weight after HFD, suggesting that
the Tnmd transgenic mice may have enhanced adipose tissue
storage capacity, which may attenuate lipid deposition in non-
adipose tissues. Transgenic mice also had signiﬁcantly smaller
BAT when compared with controls (Fig. 3e). However, no
signiﬁcant difference was detected in inguinal and axillary white
adipose tissue weights after either feeding regimens (Fig. 3e).
TNMD promotes healthy visceral adipose tissue expansion.
Because Tnmd transgenic mice had larger eWAT (Fig. 3e) and
because TNMD is required for adipogenesis (Fig. 2), white adi-
pose tissue cell size was assessed to understand whether the sig-
niﬁcant increase in eWAT weight in Tnmd transgenic mice was
due to hypertrophy or hyperplasia. Though the eWAT pads were
larger, no signiﬁcant difference in adipocyte size was observed in
eWAT or iWAT depots of HFD-fed Tnmd transgenic mice
(Fig. 4a,b), and this was also the case after a short-term (4 weeks)
HFD (Supplementary Fig. 5). These results suggest that the
increased eWAT weight (Fig. 3e) was caused by an increase in
adipocyte number rather than hypertrophy.
We thus investigated whether preadipocyte proliferation was
affected in TNMD transgenic mice. Recently, Jeffery et al.41
demonstrated that there is a signiﬁcant increase in preadipocyte
proliferation during ﬁrst week of HFD in visceral adipose tissue.
To assess preadipocyte proliferation in vivo, we treated control
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Figure 3 | Speciﬁc Tnmd expression in adipose tissue enhances HFD-induced epididymal fat expansion. (a) Schematic of transgene construct used to
generate adipose tissue-speciﬁc Tnmd transgenic mice. (b) Representative TNMD, Flag and tubulin immunoblots in iWAT, eWATand BAT lysates that were
isolated from male control (Ctrl) and transgenic mice (Tg) fed a HFD for 16 weeks. Same samples were run on different gels for TNMD. (c) Quantitative
PCR analysis of Tnmd overexpression in adipose tissues from both chow- and HFD-fed male animals. (d) Six-week-old male control (Ctrl) and transgenic
(Tg) mice were fed chow or HFD for 12 weeks. Body weights were measured at the indicated time points (HFD: n¼ 11 (control), n¼ 11 (transgenic); chow:
n¼ 11 (control), n¼ 7 (transgenic)). (e) Epididymal, inguinal and axillary white adipose tissue, brown adipose tissue and liver weights were measured in
control (Ctrl) or transgenic (Tg) male mice after 16 weeks of chow or HFD and normalized to overall body weight (mean±s.e.m.; chow: n¼ 12 (control),
n¼ 9 (transgenic); HFD: n¼ 10 (control), n¼ 11 (transgenic); *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test).
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and Tnmd transgenic mice with BrdU for 1 week in their drinking
water and concurrently fed them HFD for 6 days (Fig. 4c).
Preadipocytes were then isolated, seeded on coverslips and media
selected for 24 h followed by immunostaining for BrdU and Pref1
as a preadipocyte marker. Remarkably, a signiﬁcant increase in
BrdU incorporation was observed in preadipocytes that were
isolated from the eWAT of Tnmd transgenic mice (Fig. 4d). These
data suggest that TNMD promotes eWAT expansion by
enhancing preadipocyte proliferation in response to HFD.
Consistent with these results, mRNA levels encoding adipogenic
and lipogenic genes Plin1, sterol regulatory element-binding
protein 1c (Srebp1c), fatty acid synthase (Fasn) and ATP-citrate
lyase (Acly) were signiﬁcantly increased, and the protein levels of
PPARg, PLIN, FASN and ACLY were 1.5–1.9-fold increased in
Tnmd transgenic mouse visceral adipose tissue (Fig. 4e,f). These
observations suggest that overexpressing Tnmd in visceral adipose
tissue increases its storage capacity by both increasing adipocyte
number and upregulating lipogenesis. Although no difference in
[14C]-glucose incorporation into triglyceride was observed in
adipose tissue explants that had been isolated from chow-fed
control and TNMD transgenic animals (Supplementary Fig. 6a),
such assays performed in vitro are quite artiﬁcial and may not
represent physiological conditions.
Reduced eWAT inﬂammation and ﬁbrosis in Tnmd mice.
A previous report suggested that TNMD has antiangiogenic
properties in cultured endothelial cells45. However, TNMD
knockout mice did not display any obvious vascular
abnormalities46. These previous studies suggested that TNMD
might have effects on blood vessel density or extracellular
matrix (ECM) composition. Blood vessel morphology and
density was assessed in HFD-fed control and TNMD transgenic
mice; however, no differences were observed (Fig. 5a).
Furthermore, endothelial cell marker gene expression was
unaltered in TNMD transgenic adipose tissue as assessed by
qRT–PCR (Fig. 5b).
Interestingly, a previous report characterizing TNMD null
mice noted disorganized collagen ﬁbrils46; thus, we hypothesized
that TNMD might be involved in ECM processing. Trichrome
staining was performed in control and TNMD transgenic mice to
investigate whether TNMD is involved in regulating ECM and
tissue ﬁbrosis in eWAT. Remarkably, whereas abundant blue
collagen staining was observed in eWAT of control mice, collagen
accumulation was clearly decreased in transgenic mice, even in
the inﬂamed areas (Fig. 5c). Moreover, gene expression analysis
of whole adipose tissue revealed that genes encoding ECM
proteins such as Col1a1, Mmp12, Mmp14 as well as genes
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Figure 4 | Healthy visceral adipose tissue expansion in Tnmd transgenic mice. Six-week-old male control (Ctrl) and Tnmd transgenic (Tg) animals were
fed chow or HFD for 16 weeks as indicated. (a) Representative haematoxylin and eosin images of eWAT and iWAT (n¼ 5 (control), n¼ 9 (transgenic);
scale bar, 100mm). (b) Adipocyte size was analysed using Adiposoft software. At least four different areas per mouse were analysed, and the average
adipocyte size in each group was calculated (mean±s.e.m.; n¼ 5 (control), n¼9 (transgenic); Student’s t-test). (c) Experimental set-up for in vivo BrdU
labelling in primary preadipocytes. Six-week-old female mice were treated with 0.8mgml 1 BrdU in water containing 1% sucrose. (d) Preadipocytes were
isolated, seeded on coverslips and stained with BrdU and Pref1 antibodies. At least three different areas were quantiﬁed in each slide, and the percentage of
BrdU-positive cells were calculated (mean±s.e.m.; n¼ 5 for both group; *Po0.05, **Po0.01 by Student’s t-test). Scale bar, 50mm. (e) Quantitative PCR
and (f) western blot analysis of adipogenic and lipogenic genes in eWAT of HFD-fed male animals (mean±s.e.m.; n¼9 (control), n¼ 11 (transgenic)
(qRT–PCR); n¼ 5 (control), n¼9 (transgenic) (western blot); *Po0.05, **Po0.01 by Student’s t-test).
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involved in transforming growth factor beta signalling were
signiﬁcantly decreased in transgenic eWAT compared with
control animals suggesting that TNMD might be involved in
regulating ECM composition (Fig. 5d). Therefore, TNMD may
promote healthy visceral adipose tissue expansion through direct
interaction with ECM proteins and regulation of ECM
remodelling.
Many studies have demonstrated that inﬂammation, immune
cell inﬁltration and expansion occur in visceral adipose tissue
during obesity, which is associated with metabolic dysfunction
and insulin resistance2,21,24,25,47–49. After prolonged HFD,
immune cell inﬁltration was increased in eWAT of control
mice, whereas both transgenic lines displayed fewer crown-like
structures by histological analysis (Figs 4a and 5c; Supplementary
Fig. 7). Furthermore, qRT–PCR results demonstrated that
macrophage marker Cd68 and macrophage-derived cytokines
such as monocyte chemotactic protein 1 (Ccl2) were
downregulated by 40% in transgenic mice (Fig. 5e). Thus,
Tnmd overexpression also promotes adipose tissue integrity by
preventing adipose tissue inﬂammation in obesity.
TNMD inhibited lipid deposition in liver and BAT. Consistent
with our observation that the Tnmd transgenic mouse BAT depot
was smaller, we observed fewer lipid droplets in histological
samples of BAT (Fig. 6a). Importantly, brown adipocyte markers
such as uncoupling protein 1 (Ucp1) and PR domain containing
16 (Prdm16) were signiﬁcantly increased by nearly twofold in
transgenic mouse BAT compared with that from controls upon
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Figure 5 | Decreased inﬂammation and collagen expression in eWATof Tnmd transgenic mice. (a) Isolectin staining and vessel density quantiﬁcation in
eWAT from control and transgenic animals fed with 8 weeks of HFD (mean±s.e.m.; n¼ 5 for both control and transgenics, *Po0.05, **Po0.01, by
Student’s t-test.) Scale bars, 100mm. (b) Quantitative PCR for angiogenesis markers in eWAT from 16 weeks HFD-fed control and transgenic mice
(mean±s.e.m.; n¼ 9 (control), n¼ 11 (transgenic), *Po0.05, **Po0.01, by Student’s t-test). (c) Representative images of trichrome staining in eWAT from
control (Ctrl) and transgenic (Tg) mice that had been fed HFD for 16 weeks. Scale bar, 400mm (left panel); 100mm (middle panel); 50mm (right panel).
(d) Quantitative PCR of ECM and transforming growth factor beta signalling genes in eWAT from HFD-fed animals (mean±s.e.m.; n¼9 (control), n¼ 10
(transgenic); *Po0.05, **Po0.01, by Student’s t-test). (e) qRT–PCR analysis of inﬂammatory genes in eWAT from HFD-fed animals (mean±s.e.m.; n¼9
(control), n¼ 11 (transgenic); *Po0.05, **Po0.01, by Student’s t-test).
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HFD challenge (Fig. 6b). These results suggested that Tnmd
overexpression in BAT may also promote BAT maintenance of
mitochondrial fatty acid oxidation during HFD and contribute to
overall beneﬁcial metabolism. However, metabolic cage analysis
in HFD-fed TNMD transgenic and control mice revealed no
signiﬁcant differences in respiratory exchange ratio (RER) or VO2
consumption (Supplementary Fig. 8c,d).
A signiﬁcant decrease in liver weight was also observed in
Tnmd transgenic mice compared with their control littermates
(Fig. 3e). Therefore, we assessed hepatic lipid content in HFD-fed
mice by both histological and triglyceride analysis. Although
hepatic triglyceride content increased by twofold in control
animals fed HFD, strikingly, Tnmd transgenic animals displayed
no HFD-induced increase in hepatic triglyceride content and
instead displayed a 60% reduction compared with control HFD-
fed littermates (Fig. 6c,d). Consistent with the decreased lipid
content of livers in the HFD-challenged transgenic animals,
hepatic genes involved in lipid droplet formation that are
associated with fatty liver such as Plin2 and cell death-inducing
DNA fragmentation factor alpha (DFFA)-like effector c (Cidec)
were signiﬁcantly downregulated in HFD-fed Tnmd transgenic
mice (Fig. 6e).
Assessment of serum metabolic parameters demonstrated that
HFD-fed Tnmd transgenic animals had signiﬁcantly less total
plasma cholesterol levels. However, no differences were detected
in triglyceride levels on chow or HFD (Fig. 6f,g). Furthermore,
serum-free fatty acid levels were signiﬁcantly reduced in chow-fed
Tnmd transgenic animals (Fig. 6h). However, though serum fatty
acid levels can be a reﬂection of adipose tissue lipolysis, ex vivo
lipolysis was not affected basally or after isoproterenol stimula-
tion in Tnmd transgenic mice compared with littermate controls
(Supplementary Fig. 9a). These data suggest that adipose tissue
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Figure 6 | Peripheral lipid deposition was reduced in Tnmd transgenic mice. (a) Representative histological analysis of BAT from HFD-fed animals.
Scale bar, 100mm. (b) Quantitative PCR analysis of Ucp1, Prdm16, Pparg2, C/ebpa and C/ebpb in BAT of HFD-fed animals (mean±s.e.m.; n¼ 9 (control),
n¼ 11 (transgenic); *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test). (c,d) Livers were isolated from animals fed chow or HFD for 16 weeks.
(c) Haematoxylin and eosin staining of liver tissue. Scale bar, 100mm. (d) Triglyceride content was measured (mean±s.e.m.; n¼ 6 (control), n¼ 8
(transgenic); *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test). (e) Gene expression in livers of HFD-fed animals (mean±s.e.m.; n¼9 (control), n¼ 11
(transgenic); *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test). (f) Total cholesterol (mean±s.e.m.; chow: n¼ 12 (control), n¼ 9 (transgenic); HFD:
n¼ 10 for both group; *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test). (g) Total triglyceride (mean±s.e.m.; chow: n¼ 12 (control), n¼ 10
(transgenic); HFD: n¼ 7 for both group; *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test). (h) Free fatty acid levels (mean±s.e.m.; chow: n¼ 9
(control), n¼ 7 (transgenic); HFD: n¼ 10 (control), n¼ 11 (transgenic); *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test) were assessed in plasma
samples from control (Ctrl) and transgenic (Tg) animals after 16 weeks of chow (dashed columns) or HFD (solid columns).
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Tnmd overexpression may have a paracrine effect to regulate
serum lipid concentrations.
Improved insulin signalling in Tnmd overexpressing mice.
Because Tnmd transgenic mice displayed decreased adipose tissue
inﬂammation and less liver triglyceride content, we hypothesized
that these animals might demonstrate improved insulin sensi-
tivity. Although Tnmd transgenic mice displayed unaltered
glucose tolerance in an intraperitoneal glucose tolerance test on
chow or HFD (Fig. 7a), they were remarkably more insulin
responsive than their control littermates on both chow and HFD
during an insulin tolerance test (Fig. 7b). These data suggest that
adipose-speciﬁc overexpression of TNMD improves systemic
insulin sensitivity.
To determine whether insulin sensitivity was also enhanced in
Tnmd transgenic mice at the molecular level in insulin-responsive
tissues, HFD-fed control and Tnmd transgenic mice were injected
with either insulin or PBS. Then, 15min later, muscle, liver and
eWAT were isolated from animals and analysed for phospho-Akt
levels as an indicator of insulin signalling. Akt phosphorylation at
both S473 and T308 sites as detected by speciﬁc anti-
phosphoserine and anti-phosphothreonine antibodies was sig-
niﬁcantly increased in Tnmd transgenic mouse eWAT compared
with littermate controls. Moreover, a trend towards an increased
Akt phosphorylation at these sites was observed in both liver and
muscle, suggesting that in addition to improving adipose tissue
insulin sensitivity, adipose TMND might also improve insulin
responsiveness in other peripheral tissues (Fig. 7c,d). To further
assess what tissues contributed to the enhanced insulin sensitivity
in Tnmd transgenic mice, hyperinsulinemic–euglycemic clamps
were performed. The clamp data demonstrated that although
glucose levels during the clamp were similar, Tnmd transgenic
animals had higher insulin sensitivity compared with control
littermates as assessed by glucose infusion rate (Fig. 8a,b). This
difference could be attributed to improved hepatic insulin
sensitivity because Tnmd transgenic animals displayed decreased
hepatic glucose production (Fig. 8c), whereas no differences were
observed in tissue-speciﬁc glucose uptake (Fig. 8d,f). Collectively,
these data suggest that Tnmd overexpression in murine adipose
tissue improves systemic insulin sensitivity.
Discussion
Identiﬁcation of factors that modulate pathological consequences
of obesity is a vital step towards development of novel therapeutic
approaches to treatment of insulin resistance and other aspects of
metabolic syndrome. In this study, we demonstrated that insulin-
resistant obese individuals have increased TNMD expression
a b
c
Insulin – +
Ctrl Tg 
p-AKT (S473)
t-AKT
p-AKT (T308)
+– + – – + + + +
15 30 60 90
0
100
200
300
400
0 0 15 30 60 90 120
0 15 30 60 90 120
0
25
50
75
100
0
25
50
75
100
0
100
200
300
400
500
Ctrl
Tg
Ctrl
Tg
Tg Tg
– +
Ctrl Tg 
+– + – – + + + + – +
Ctrl Tg 
+– + – – + + + +
d
Ctrl (PBS)
Ctrl (insulin)
 S473 T308
0
1
2
3
4
S473 T308
0
1
2
3
4
5
eWAT Liver Muscle
eWAT Liver
TimeTime
Ch
ow
gl
uc
os
e 
(m
g d
l–1
)
H
FD
gl
uc
os
e 
(m
g d
l–1
)
Ch
ow
gl
uc
os
e 
(%
 ov
er 
ba
sa
l)
H
FD
gl
uc
os
e 
(%
 ov
er 
ba
sa
l)
GTT ITT
50 kDa
50 kDa
50 kDa
S473 T308
0.0
0.5
1.0
1.5
2.0 Muscle
Tg (insulin)
Tg (PBS)
R
el
at
iv
e 
pr
ot
ei
n
(pA
KT
/tA
KT
)
*
**
120
15 30 60 900 120
Ctrl Ctrl
*
*
*
**
*
Figure 7 | TNMD increased Akt phosphorylation in eWAT and improved systemic insulin sensitivity. (a) Glucose tolerance and (b) insulin tolerance
tests were performed in male control (Ctrl) or transgenic (Tg) mice after 12 weeks of chow or HFD (mean±s.e.m.; chow: n¼ 12 (control), n¼ 10
(transgenic); HFD, n¼ 11 (control), n¼ 13 (transgenic); *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test). (c,d) Male control (Ctrl) and transgenic (Tg)
mice that were fed with HFD for 12 weeks. Mice were fasted for 4 h and tissues were collected 15min after PBS or insulin injection. (c) Western blot
analysis and relative protein levels for p-Akt (S473), p-Akt (T308) and total Akt in eWAT, liver and muscle tissue lysates. (d) Densitometric analysis of
c (mean±s.e.m.; n¼4 (control and transgenic, PBS), n¼ 5 (control, insulin), n¼ 7 (transgenic, insulin), *Po0.05, **Po0.01, ***Po0.001, by Student’s t-test).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10686 ARTICLE
NATURE COMMUNICATIONS | 7:10686 |DOI: 10.1038/ncomms10686 | www.nature.com/naturecommunications 9
compared with insulin-sensitive controls in the omental adipose
depot, even when matched for BMI (Fig. 1b,c). Previous studies
demonstrated that TNMD is highly expressed in human adipose
tissue and its expression is further increased in obese condi-
tions31. Furthermore, genetic studies that investigated an
association between single-nucleotide polymorphisms and
various metabolic markers suggested a potential role for this
gene in adipose tissue in disease37. Though no difference in
TNMD expression was observed in insulin-resistant versus
insulin-sensitive patients in subcutaneous adipose tissue depots,
previous studies that analysed subcutaneous adipose tissue
biopsies demonstrated a correlation of TNMD expression,
fasting serum insulin levels and homeostatic model
assessment-insulin resistance (HOMA-IR) in obese patients31,33.
TNMD expression is predominantly in adipocytes compared with
the SVF (Fig. 1d), suggesting that the expression differences
observed in insulin-sensitive versus insulin-resistant individuals
mainly result from expression changes in primary adipocytes.
A key ﬁnding in this study is that TNMD is required for
differentiation of human SGBS and mouse 3T3-L1 preadipocytes
(Fig. 2). Because TNMD expression is readily stimulated after
adipogenic induction and continues to increase during differ-
entiation in human cells, we supposed that the absence of TNMD
in preadipocytes would impair early differentiation. Consistent
with this notion, when TNMD expression was silenced, expres-
sion of transcription factors involved in adipogenesis such as
C/EBPA and PPARG was decreased at early time points of
differentiation (Fig. 2f,g), and adipogenesis was impaired. While
the exact function of TNMD in this process is unclear, TNMD is
hereby identiﬁed as a novel required factor in early stages of
adipocyte differentiation. TNMD expression is actually decreased
2 days after induction of 3T3-L1 cell adipogenesis. Therefore, unlike
the case in human cells, its expression is actually higher in mouse
preadipocytes when compared with mature adipocytes. However,
silencing of TNMD before induction was sufﬁcient to inhibit the
adipogenesis of these mouse preadipocytes, showing that TNMD is
required for the initiation of adipogenesis in both species.
Because it appeared TNMD had a potential role in human cells
and human patients but was expressed at low levels in mouse
adipose tissue, we sought to address the role of TNMD in adipose
tissue by generating a mouse model with higher adipose tissue-
speciﬁc Tnmd expression. Such adipose-speciﬁc Tnmd expression
in transgenic mice increased adipogenic and lipogenic gene and
protein expression in eWAT upon HFD feeding. Notably,
PPARg, one of the major regulators of glucose metabolism and
adipocyte function50–52, was signiﬁcantly upregulated in the
eWAT of HFD-fed Tnmd transgenic mice compared with their
control littermates (Fig. 4f). Because activation of PPARg
has many beneﬁcial effects on adipose tissue including
improving lipid metabolism and decreasing serum free fatty
acids (FFAs)53–55, it can be inferred that TNMD strongly
inﬂuences adipogenesis through regulating PPARg expression
in vivo. Consistent with these ﬁndings in vivo, silencing TNMD
signiﬁcantly reduced adipocyte differentiation and adipogenic
gene expression, including PPARG in human and mouse
preadipocytes in vitro.
Many recent studies have described that the ECM has a critical
function to regulate adipose tissue homeostasis in obesity56–60,
and exogenous signals regulated by ECM proteins are involved in
determining the fate of mesenchymal progenitor cells. For
example, ECM stiffness and composition regulates Wnt and
transforming growth factor beta signalling, which has an
inhibitory or, in some cases, stimulatory role in adipogenesis15.
Adipose tissue ECM also provides a suitable environment for
changes in cell shape during adipogenesis and cell expansion61–64.
In this study, we noted a reduction in collagen staining in
Tnmd transgenic adipose tissue, and collagen and matrix
metalloproteinase gene expression was also signiﬁcantly reduced
in Tnmd overexpressing adipose tissue (Fig. 5). These results
suggest that TNMD may promote beneﬁcial adipogenesis at least
in part by modulating properties of the ECM in adipose tissue.
In addition to enhancing insulin signalling in eWAT, beneﬁcial
effects of TMND in the liver was also observed, which enhanced
systemic insulin sensitivity (Figs 6 and 7). Tnmd transgenic mice
had reduced hepatic lipid deposition and were more responsive to
insulin even in lean, chow-fed conditions. Furthermore, hepatic
glucose production was reduced in TNMD transgenic animals
(Fig. 8). However, it is not established whether these peripheral
effects are due to the improved lipid sequestration and decreased
inﬂammation in eWAT. Future studies will investigate the
Basal Clamp
0
100
200
300
400
Glucose Hepatic glucose
production
Ctrl
Tg
Ctrl
Tg
Ctrl
Tg
Basal Clamp
0
5
10
15
20
25
Ctrl Tg
0
1
2
3
Glucose
infusion rate
Ctrl Tg0
200
400
600
Ctrl Tg
0
200
400
600
800
Ctrl Tg
0
2
4
6
8
10
eWAT
glucose uptake
BAT
glucose uptake
Skeletal muscle
glucose uptake
m
g 
dl
–
1
m
g 
kg
–
1  
m
–
1
m
g 
kg
–
1  
m
–
1
*
*
n
m
o
l g
–
1  
m
in
–
1
n
m
o
l g
–
1  
m
in
–
1
n
m
o
l g
–
1  
m
in
–
1
a b c
d e f
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mechanisms by which adipose TNMD function might cause
beneﬁcial signalling to other tissues.
Tnmd transgenic mice had smaller BAT with fewer lipid
droplets after HFD (Figs 3e and 6a). Furthermore, thermogenic
genes Ucp1, Prdm16 and Pparg were upregulated in transgenic
animals compared with their littermate controls (Fig. 6b).
PRDM16 and PPARg are not only involved in BAT differentia-
tion but also in BAT maintenance along with UCP1 (refs 65,66).
However, though TNMD was overexpressed in BAT in this
model, thermogenic capacity of the animals as assessed by RER
remained unchanged (Supplementary Fig. 8d). Future studies will
utilize thermoneutral or cold challenge conditions to assess
whether TNMD has a role in regulation of BAT energy
expenditure.
TNMD expression was higher in the human insulin-resistant
cohort in our study, yet paradoxically mice overexpressing Tnmd
in adipose tissue displayed improved insulin sensitivity (Figs 7
and 8). In humans, omental fat from insulin-resistant subjects
displays more inﬂammation and larger adipocytes compared with
BMI-matched insulin-sensitive subjects2. It is possible that the
increased inﬂammation in these insulin-resistant subjects arises
from enhanced adipocyte death in the insulin-resistant omental
fat. Indeed, a correlation between cell death, insulin resistance
and adipocyte size has previously been reported67. Thus, we
speculate that TNMD might be increased in insulin-resistant
omental fat to increase adipocyte replenishment in these
conditions42,68. Indeed, increased preadipocyte proliferation was
observed in TNMD transgenic animals (Fig. 4), which could
promote healthy tissue expansion. It is also possible that either
the omental fat microenvironment or endocrine signals
associated with the insulin-resistant state can contribute to
TNMD overexpression, perhaps as a compensatory mechanism to
promote adipogenesis and increase insulin responsiveness.
Finally, most of the insulin-resistant human subjects in our
cohort had been treated for different amounts of time with
various medications including thiazolidinediones before bariatric
surgery and tissue collection. Thus, we cannot rule out the
possibility that TNMD expression was increased in insulin-
resistant subjects as a result of these medications.
In summary, our study reveals that the gene TNMD, which is
highly expressed in human adipose tissue, encodes a protective
adipose tissue factor that promotes preadipocyte proliferation,
adipogenesis, adipose tissue health and insulin responsiveness
in vivo. The data presented herein support the hypothesis that
TNMD contributes to beneﬁcial visceral adipose tissue expansion
that protects against metabolic dysfunction. Because adipose
TNMD expression improves insulin sensitivity systemically, it
may have potential as a therapeutic target to protect metabolic
homeostasis in obesity.
Methods
Animals. All of the studies were approved by The University of Massachusetts
Medical School Institutional Animal Care and Use Committee. Mice were housed
in an animal facility with a 12 h light/dark cycle and had access to water, chow
or HFD (12492i Harlan) ad libitum during the indicated periods. For in vivo
preadipocyte proliferation studies, mice were treated with 0.8mgml 1 BrdU in
water with 1% sucrose. Water was changed every 72 h and kept in the dark. Mice
were killed by CO2 and bilateral pneumothorax.
Human samples. Human adipose tissue samples were collected from morbidly
obese patients who underwent gastric bypass surgery between 2005 and 2009 at the
University of Massachusetts Medical School were selected for this study2. Samples
used for microarray analysis were from BMI-matched female patients, whereas
qRT–PCR and western blot validations were performed in samples from both
males and females. Adipose tissue samples were obtained from lower abdominal
wall (for subcutaneous) and omentum (for visceral) during the surgery. Informed
consent was given by the patients and the study was approved by University of
Massachusetts Medical School Institutional Review Board.
Generation of adiponectin-Tnmd-ﬂag transgenic mice. Full-length mouse Tnmd
with a C-terminal Flag tag was inserted 30 to 5.4-kb adiponectin promoter at the
Cla I site69. After verifying both ends by sequencing, the transgenic cassette was
linearized by Kpn1 and Xho1 digestion, puriﬁed and submitted for pro-nuclear
injection. The transgene was introduced into embryos from C57BL/6J mice
(000058; Jackson Laboratories). Embryos were then implanted into
pseudopregnant C57BL6/J females by the UMASS Transgenic Animal Facility.
Male transgenic animals were crossed with C57BL6/J females. Genotyping was
performed by PCR from genomic DNA with the following primers: 50-
GACCAGAATGAGCAATGGGTG, 30-ATCGTCGTCATCCTTGTAGTCG-30 .
Six- to eight-week-old Adiponectin-Tnmd-Flag transgenic mice and age-matched
wild-type littermates were used in the experiments. Male animals were used unless
otherwise was stated.
Western blotting. Cell lysates were prepared using RIPA buffer (150mM NaCl,
50mM Tris pH 7.4, 1% sodium deoxycholate, 1% NP-40, 0.2% SDS, 50mM
EDTA) containing 1X HALT protease and phosphatase inhibitors (Thermo
Scientiﬁc). Total protein was separated on SDS–polyacrylamide gel electrophoresis
gels and transferred to nitrocellulose membranes. Membranes were blocked with
5% milk solution in TBS-T and immunoblotted with an antibody generated against
NGIEFDPMLDERGYC peptide from C terminus of TNMD (Rockland, 1:5,000)
and antibodies against C/EBPa (8178), C/EBPb (3082), PPARg (2443), phospho-
AKT(S308) (9275), phospho-AKT(T473) (4060), total AKT (4691 or 2920), ACLY
(4332), ACC (3662), PLIN (3470), (Cell Signaling, 1:1,000), FASN (BD Biosciences,
610963, 1:2,000), FLAG (F7425, 1:2,000) tubulin and actin (Sigma, 1:5,000).
Uncropped gel pictures are provided in Supplementary Figs 10 and 11.
qRT–PCR analysis. Total RNA was isolated using TriPure (Roche) according to
the manufacturer’s protocol. DNAse (DNA-free, Life Technologies)-treated RNA
was reverse transcribed into complementary DNA using iScript (BioRad).
Quantitative PCR analyses were performed using SYBR green (iQ SYBR Green
Supermix, BioRad) on BioRad CFX97. Primer sequences used for qRT–PCR
analyses were listed in Supplementary Table 2. HUGO Gene Nomenclature
Committee’s Guideline was used for gene names written in this manuscript.
Cell culture. SGBS cells were obtained from Dr Martin Wabitsch’s laboratory and
cultured in DMEM/F12 media supplemented with 10% fetal bovine serum (FBS),
33 mM biotin, 17 mM pantothenic acid 100Uml 1 penicillin and 0.1mgml 1
streptomycin until full conﬂuence. Cells were washed with PBS before differ-
entiation was stimulated with serum-free media containing rosiglitazone,
dexamethasone, 3-isobutyl-1-methylxanthine, cortisol, transferrin, triiodotyronin
and human insulin. Four days later, the differentiation cocktail was replaced with
adipocyte maintenance media (DMEM/F12, biotin, pantothenic acid, transferrin,
insulin and cortisol). Cells were maintained until they are fully differentiated
(day 14). 3T3-L1 preadipocytes were obtained from AATC (CL-173). Cells were
cultured in high-glucose DMEM media supplemented with 10% FBS, 50 mgml 1
streptomycin and 50Uml 1 penicillin and differentiated into adipocytes with
high-glucose DMEM media with 10% FBS, 50 mgml 1 streptomycin, 50Uml 1
penicillin, 5 mgml 1 insulin, 0.25 mM dexamethasone and 0.5mM 3-isobutyl-1-
methylxanthine.
Oil Red O staining. Differentiated adipocytes were ﬁxed with 10% formalin,
washed with 60% isopropanol and air dried. Oil Red O working solution was added
on cells and washed with distilled water to remove excess dye. Oil Red O was
extracted using 100% isopropanol and absorbance was measured in 520 nm in
spectrometer for quantiﬁcation.
siRNA transfection of SGBS and 3T3-L1 preadipocytes. SGBS or 3T3-L1
preadipocytes were plated into 12-well plates (105 cells per well) and transfected
with 100 nM (SGBS) or 50 nM (3T3-L1) scrambled siRNA or TNMD siRNA
(Dharmacon, siGENOME, Smartpool) using Lipofectamine RNAiMax (Life
Technologies) according to the manufacturer’s protocol. Forty-eight hours after
transfection, cells were collected or stimulated for adipogenesis. siRNA sequences
for mouse and human TNMD were provided in Supplementary Table 3.
MTT assay. SGBS preadipocytes (104 cells per well) were plated in 96-well plates.
Twenty-four hours later, they were transfected with either scrambled or TNMD
siRNA. Cell viability was measured 0, 24 and 48 h after transfection using an MTT
assay kit (Biotium Inc.) according to the manufacturer’s instructions.
Immunoﬂuorescence staining. Differentiated adipocytes were ﬁxed with 10%
formalin and permeabilized in 0.1% Triton X in PBS. Bovine serum albumin (BSA;
3%) in PBS was used for blocking. Cells were incubated overnight with PLIN
antibody (Cell Signaling) diluted in 1% BSA solution and 45min at 37 C with
secondary antibody (Alexa Fluor 488, Life Technologies). Nuclei were stained with
4,6-diamidino-2-phenylindole. Preadipocytes were ﬁxed in 70% cold methanol and
treated with 1.5M HCl for 30min. After washing, they were washed and blocked
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with 5% normal goat serum and 0.3% Triton X-100 in PBS. Primary antibodies for
BrdU and Pref1 (Cell Signaling, 5292, 1:1,000 and EMD Millipore, AB3511, 1:100)
were applied overnight. Cells were washed and incubated with secondary anti-
bodies for 90min at room temperature and mounted with Prolong Gold Antifade
Reagent with 4,6-diamidino-2-phenylindole. Images from at least three different
areas were taken, and nuclei were counted by Image J Analysis Software. For vessel
density in adipose tissue, whole-mount staining was performed after 10% formalin
ﬁxation. Tissues were blocked overnight in 10% BSA and 0.3% triton X-100 in PBS
at 4 C, stained overnight with Isolectin B4 (Life Technologies I21411; 1:40) in
100mMMgCl2, 100mM CaCl2, 10mMMnCl2 and 1%Triton X-100 in PBS at 4 C,
and washed three times at 20min in 5% BSA, 0.15% triton X-100 in PBS at room
temperature. Approximately, 1-mm cubes were whole mounted in ProLong Gold
(Life Technologies). Images were visualized in ﬂattened 25-mm z-stacks with
confocal microscopy at  10. Images were acquired with MetaMorph Software,
version 6.1 (Universal Imaging, Downingtown, PA). At least three technical
replicates of adipose tissue images were quantiﬁed per mouse and averaged for
average vascular density. Images were quantiﬁed using Image J Analysis Software.
Histology. Tissue samples were ﬁxed in 10% formalin and embedded in parafﬁn.
Sectioned slides then stained with haematoxylin and eosin by the UMass Medical
School Morphology Core. Adipocyte size was assessed using Adiposoft software70.
Insulin and glucose tolerance tests. Mice fed with the indicated diets were fasted
16 hours for glucose tolerance tests and 4 hours for insulin tolerance tests. Basal
blood glucose was measured with a Breeze-2-glucose meter (Bayer) before and after
they were intraperitoneally injected with glucose (1 g kg 1) or insulin (1 IU kg 1).
Hyperinsulinemic–euglycemic clamp and metabolic cage studies. The clamp
and metabolic cage studies were performed at the UMass Mouse Metabolic
Phenotyping Center. Mice fed with HFD for 12 weeks were subjected to a 4-h fast,
and a 2-h hyperinsulinemic–euglycemic clamp was performed with a primed and
continuous infusion of human insulin (150mUkg 1 body weight priming
followed by 2.5mUkg 1 min 1; Humulin, Eli Lilly). During the clamp, 20%
glucose was infused at variable rates to maintain euglycemia71. Whole-body glucose
turnover was assessed with a continuous infusion of [3-3H]glucose, and 2-deoxy-D-
[1-14C]glucose (PerkinElmer, Waltham, MA) was administered (10 mCi) at 75min
after the start of clamps to measure insulin-stimulated glucose uptake in individual
organs. At the end of the study, mice were anaesthetized, and tissues were taken for
biochemical analysis. The metabolic cages were used to measure food intake, RER,
VO2 consumption and physical activity over a 3-day period, and average for each
parameter was calculated (TSE Systems).
Plasma analysis. Blood samples were collected from animals after a 16-h fast via
cardiac puncture. Serum triglyceride levels were measured using a Serum Trigly-
ceride Determination Kit (Sigma). Free fatty acid and total cholesterol in plasma
samples were analysed using NEFA (Free Fatty Acid) Kit (Wako Diagnostics) and
Cholesterol/Cholesteryl Ester Quantitation Kit (Abcam), respectively.
Ex vivo lipogenesis assay. Adipose tissue explants were incubated with labelling
media containing 2.50% fatty acid-free BSA, 1% (v/v) Pen/Strep, 0.5mM D-glucose,
2mM sodium pyruvate, 2mM glutamine and 2 mCiml 1 [14C]-U-glucose. Insulin
(1mM) was added to insulin-stimulated conditions and incubated for 4.5 h before
lipid extraction at 37 C. The reaction was stopped by adding modiﬁed Dole’s
extraction mixture (80ml isopropanol, 20ml hexane and 2ml 1N H2SO4). Total
triglyceride was extracted with hexane, washed and evaporated, and counted by
liquid scintillation.
Ex vivo lipolysis assay. Adipose tissue explants were isolated from iWAT and
eWAT of mice that had been fed chow diet for 12 weeks. Fat pads were measured,
and a 30-mg piece was placed in freshly prepared KRH buffer (125mM NaCl,
5mM KCl, 1.8mM CaCl2, 2.6mM MgSO4 and 5mM HEPES, pH 7.2) containing
2.5% BSA (fatty acid free) and 1mM sodium pyruvate until stimulation.
Subsequently, extracts were treated with PBS or isoproterenol (10mM) for 2 h at
37 C. Free glycerol content in the buffer was quantiﬁed for each sample using the
Free Glycerol Determination Kit (Sigma). Glycerol release from each sample was
normalized to the weight of each fat pad.
Statistical analysis. A two-tailed Student’s t-test with Welch’s correction was
performed to analyse the difference between two groups using Microsoft Excel or
Graph Pad Prism 6.0. The Grubb’s test was used to determine the statistical
outliers. In case of an outlier was determined, it was removed from the statistical
analysis. Experimental data were represented as the mean of at least three biological
replicates. P valueso0.05 were considered to be statistically signiﬁcant. Variance
was estimated using the s.e. of the mean for both group that are statistically
compared. No statistical methods were used to predict sample size. No randomi-
zation or blinding was performed to allocate the samples for animal experiments.
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